Advanced search×

Second primary cancers in patients with cutaneous malignant melanoma: a population-based study in Sweden.

Br J Cancer 73(2):255-9 (1996) PMID 8546916

To quantify the risk of second primary cancers among patients with cutaneous malignant melanoma, we studied 20,354 patients in the Swedish Cancer Register during 1958-88. A second primary cancer was reported in 1605 patients, compared with an expected number of 1109.5 [standardised incidence ratio (SIR) = 1.45, 95% confidence interval (CI) = 1.38-1.52]. The highest risk was found among patients younger than 60 years. The greatest risk was seen during the first year after diagnosis (SIR = 1.91, CI = 1.69-2.14), but even after long-term follow-up--15 years or more--the risk was still significantly elevated (SIR = 1.56, CI = 1.35-1.79). The strongest association was found for a second primary malignant melanoma (men, SIR = 10.0, CI = 8.26-12.00; women, SIR = 8.66, CI = 7.22-10.30) and non-melanoma skin cancer (men, SIR = 3.58, CI = 2.85-4.44; women, SIR = 2.41, CI = 1.71-3.29). The risk of second cancers associated with tissues of neuroectodermal origin was increased, especially tumours of the nervous system (men, SIR = 1.73, CI = 1.10-2.60; women, SIR = 2.03, CI = 1.45-2.78). The SIR of second cancers involving the immune system was also increased. An excess risk of endometrial cancer was seen (SIR = 1.41, CI = 1.03-1.88), but no significant associations existed for cancers of the breast, ovary, testis or other endocrine glands. Among tumours of the digestive tract, only colon cancer in men had a significantly increased SIR (1.33, CI = 1.00-1.74).

DOI: 10.1038/bjc.1996.45
Version: za2963e q8zad q8zb1 q8zc3 q8zda q8zef q8zf6 q8zg9

Similar articles you may find interesting…

  1. The study design and rationale of the randomized controlled trial: translating COPD guidelines into primary care practice.

    BMC Fam Pract 14(1):56 (2013) PMID 23641803

    We will also examine the use of a patient activation tool - 'MyLungAge' - to prompt patients at risk for or who have COPD to request spirometry confirmation and to request support for smoking cessation if a smoker. DISCUSSION: Using a multi-modal intervention of patient activation and a technology-s...
  2. n-3 fatty acids in patients with multiple cardiovascular risk factors.

    N Engl J Med 368(19):1800-8 (2013) PMID 23656645

    We evaluated the potential benefit of such therapy in patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction. In this double-blind, placebo-controlled clinical trial, we enrolled a cohort of patients who were fol...
  3. n-3 fatty acids in patients with multiple cardiovascular risk factors.

    N Engl J Med 368(19):1800-8 (2013) PMID 23656645

    We evaluated the potential benefit of such therapy in patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction. In this double-blind, placebo-controlled clinical trial, we enrolled a cohort of patients who were fol...